--- title: "U.S. stock market midday update: Moderna rises 9.56% on increased volume, cancer vaccine news triggers short covering" type: "News" locale: "en" url: "https://longbridge.com/en/news/297689025.md" description: "Moderna rose 9.56%; AbbVie rose 1.39%, with a transaction volume of USD 517 million; Amgen rose 1.51%, with a transaction volume of USD 471 million; Gilead Sciences rose 1.73%, with a transaction volume of USD 355 million; Vertex Pharmaceuticals rose 0.61%, with a market value of USD 138.9 billion" datetime: "2026-09-01T19:13:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297689025.md) - [en](https://longbridge.com/en/news/297689025.md) - [zh-HK](https://longbridge.com/zh-HK/news/297689025.md) generator: "portal-rs" --- # U.S. stock market midday update: Moderna rises 9.56% on increased volume, cancer vaccine news triggers short covering **U.S. Stock Market Midday Update** Moderna rose 9.56%, with increased trading volume. Based on recent key news: 1. On August 31, positive news emerged regarding the cancer vaccine jointly developed by Moderna and Merck, leading to a surge of approximately 150% in Moderna's stock price this month. Short sellers were forced to cover their positions, severely impacting many quantitative funds and hedge funds. Source: MarketBeat 2. On September 1, clinical trial results for Moderna's personalized cancer vaccine showed significant improvement in disease-free survival and distant metastasis-free survival for high-risk melanoma patients. This breakthrough validated the application of mRNA technology beyond infectious diseases, driving an overall rise in the biotechnology sector. Source: Benzinga 3. On August 30, the commercialization prospects for personalized tumor vaccines became apparent, pushing Moderna's stock price higher. This vaccine requires algorithms to understand each patient's tumor and complete the unique drug production within weeks. Source: Zhitong Finance. The biotechnology sector performed strongly overall, with noticeable capital inflows. **Top Stocks by Trading Volume in the Industry** AbbVie rose 1.39%. Based on recent news: 1. On August 31, AbbVie announced its participation in the 21st Annual Healthcare Conference hosted by Wells Fargo on September 9. Management will hold a fireside chat at the conference, and investors expect the company to share its future development strategy, driving the stock price up. 2. On September 1, AbbVie's SkinMedica® released new data on its chemical peel products, showing significant improvement in effectiveness from week 2 to week 4, enhancing market confidence in the company's product line and promoting stock price growth. 3. On August 31, market analysts recommended AbbVie as a high-quality investment choice, citing its high dividend yield, which attracted more investor attention and further pushed the stock price up. The healthcare sector has performed strongly recently, with noticeable capital inflows. Amgen rose 1.51%. Based on recent key news: 1. On August 31, Amgen's cholesterol-lowering drug Repatha showed a 20% reduction in mortality risk in clinical trials, enhancing market confidence in the drug and driving the stock price up. 2. On September 1, Amgen faced the risk of withdrawal of its Tavneos drug from the U.S. and European markets. Although the company is challenging this decision, regulatory issues continue to exert pressure on the stock price. 3. On September 1, analysts maintained a hold rating on Amgen. Despite significant sales growth for Repatha, it failed to make the analysts' top five recommended stocks list. Competition for innovative drugs in the pharmaceutical industry has intensified, with increasing regulatory risks. Gilead Sciences rose 1.73%. Based on recent key news: 1. On September 1, ARTISTRY-2 trial results indicated that switching to the drug had no significant impact on patient weight. Following this news, Gilead Sciences' stock price rose by 0.49% 2. On August 31, the biomedical industry development mechanism in Pingshan District, Shenzhen provided precise services for enterprises, promoting the high-quality development of the biomedical industry. This move further enhanced market confidence in the biomedical sector. 3. On August 31, Qinhao Pharmaceutical disclosed its massive debt and R&D investment situation, stating that the cooperation agreement with Gilead included arrangements for future milestone payments. This news had a positive impact on the stock price of Gilead Sciences. The biomedical industry has shown strong performance recently, with significant policy support. **Stocks ranked at the top of the industry market capitalization** Futai Pharmaceutical rose by 0.61%. Based on recent news, 1. On September 1, Vertex Pharmaceuticals released research results on its single-dose drug, showing that the drug significantly reduced lipid levels within a year. This news boosted market confidence in the biopharmaceutical industry, driving up Futai Pharmaceutical's stock price. 2. On August 30, MarketBeat pointed out that although Vertex Pharmaceuticals currently has a moderate buy rating among analysts, top analysts believe there are five stocks that are more worthy of purchase. This news may lead investors to reassess the investment value of Futai Pharmaceutical, further driving up its stock price. 3. On September 1, Constellation Brands plans to expand its low-calorie and non-alcoholic product lines to cater to health trends. This industry trend may indirectly affect the market performance of Futai Pharmaceutical, boosting its stock price. Confidence in the biopharmaceutical industry has strengthened, with significant capital inflow ### Related Stocks - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md) - [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md) ## Related News & Research - [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md) - [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md) - [Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It](https://longbridge.com/en/news/298134130.md) - [Moderna Raises $3.0 Billion via 2032 Zero-Coupon Converts; Adds Capped Calls to Limit Dilution](https://longbridge.com/en/news/297697426.md) - [Wolfe Research Just Upgraded Moderna Stock. Here's Why.](https://longbridge.com/en/news/296951590.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**